SK bioscienceLtd Dirección

Dirección controles de criterios 1/4

El CEO de SK bioscienceLtd's es Jae-Yong Ahn, nombrado en Mar 2021, tiene una permanencia de 3.08 años. posee directamente un 0.057% de las acciones de la empresa, con un valor de ₩2.55B. La antigüedad media del equipo directivo y de la junta directiva es de 1.5 años y 3.3 años, respectivamente.

Información clave

Jae-Yong Ahn

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	3.3yrs
Participación del CEO	0.06%
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

SK bioscienceLtd's (KRX:302440) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 23

CEO

Jae-Yong Ahn (57 yo)

3.3yrs

Permanencia

Mr. Jae-Yong Ahn is the Chief Executive Officer and President of SK bioscience Co.,Ltd since March 2021 and served as its Chairman since March 2021. He serves as Executive Officer and Director of VAX Busi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jae-Yong Ahn	CEO, President & Director	3.3yrs	sin datos	0.057% ₩ 2.2b
Harry Kleanthous	Executive Vice President of Vaccine R&D Strategy & External Innovation	1.7yrs	sin datos	sin datos
Sally Choe	Head of Global Clinical Development & Regulatory Affairs	1.7yrs	sin datos	sin datos

1.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de A302440 no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jae-Yong Ahn	CEO, President & Director	no data	sin datos	0.057% ₩ 2.2b
Hoon Kim	Executive Director	3.3yrs	sin datos	0.057% ₩ 2.2b
Kwon Ik-Hwan	Independent Chairman of the Board	3.3yrs	sin datos	sin datos
Moon Chang-Jin	Independent Outside Director	3.7yrs	sin datos	sin datos
Choi Jeong-Wook	Independent Outside Director	3.7yrs	sin datos	sin datos

3.5yrs

Permanencia media

Junta con experiencia: La junta directiva de A302440 se considera experimentada (3.3 años de antigüedad promedio).

SK bioscienceLtd Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

SK bioscience Co.,Ltd., Annual General Meeting, Mar 25, 2024

High number of new and inexperienced directors

SK bioscience Announces Executive Appointments

Less than half of directors are independent

Recent updates

Consensus EPS estimates fall by 59%

Insufficient new directors

SK bioscienceLtd's (KRX:302440) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings released: EPS: ₩291 (vs ₩1,596 in FY 2022)

SK bioscience Co.,Ltd., Annual General Meeting, Mar 25, 2024

SK Bioscience Obtains Prequalification Certification from the World Health Organization

Consensus revenue estimates fall by 13%

Consensus EPS estimates fall by 12%, revenue upgraded

SK bioscience Co.,Ltd. to Report Q4, 2023 Results on Feb 01, 2024

Price target decreased by 7.5% to ₩56,714

SK bioscience Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Consensus revenue estimates increase by 15%

Investor sentiment improves as stock rises 17%

Consensus revenue estimates decrease by 17%

SK bioscience Co.,Ltd. to Report Q2, 2023 Results on Jul 28, 2023

Consensus estimates of losses per share improve by 59%

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

Price target decreased by 8.2% to ₩59,875

Consensus revenue estimates decrease by 34%

Investor sentiment improves as stock rises 17%

Consensus EPS estimates fall by 12%, revenue upgraded

Consensus revenue estimates fall by 18%

Price target decreased by 13% to ₩75,545

SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs

SK bioscience Co.,Ltd. to Report Q4, 2022 Results on Feb 08, 2023

SK Bioscience Co.,Ltd. Receives Expanded Manufacturing and Marketing Approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid

SK Bioscience Receives Biologics License Application Approval of the Skyzoster™ from the National Pharmaceutical Regulatory Agency in Malaysia

High number of new and inexperienced directors

Price target decreased to ₩103,400

Price target decreased to ₩114,700

SK bioscience Announces Executive Appointments

SK bioscience Co.,Ltd. to Report Q3, 2022 Results on Oct 31, 2022

Price target decreased to ₩124,300

Consensus EPS estimates fall by 11%

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

SK bioscience Receives Post Approval Change Application Approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid™ (NVX-CoV2373) COVID-19 Vaccine

Consensus EPS estimates fall by 11%

Consensus revenue estimates fall by 11%

Price target decreased to ₩151,667

Consensus revenue estimates fall by 10%

Investor sentiment improved over the past week

Price target decreased to ₩167,222

Price target decreased to ₩167,222

Consensus EPS estimates fall by 12%

Investor sentiment deteriorated over the past week

Price target decreased to ₩192,250

Consensus EPS estimates fall by 17%

Price target decreased to ₩216,250

Less than half of directors are independent

Price target decreased to ₩225,714

Investor sentiment deteriorated over the past week

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

SK Bioscience and GSK Start Phase 3 Trial of Adjuvanted Covid-19 Vaccine Candidate

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media